Utilização de plataforma gênica no prognóstico do câncer de mama

##plugins.themes.bootstrap3.article.main##

Paula Gabriela Casa Cesar
Fernando Luiz Affonso Fonseca
Flávia de Sousa Gehrke
Beatriz da Costa Aguiar Alves
Renata Kelly Kuniyoshi
Auro Del Giglio

Resumo

O câncer de mama é o principal tipo de câncer que acomete as mulheres no mundo. Muitos são os fatores que estão associados ao aparecimento e desenvolvimento desse tipo de tumor. Há grande variabilidade interindividual tanto na idade da mulher no momento do diagnóstico de câncer de mama quanto na expressão fenotípica existente nesse mesmo momento, o que torna o diagnóstico desafiante para qualquer pesquisador. Na última década, houve melhor entendimento sobre os mecanismos moleculares envolvidos na progressão do câncer de mama e sobre o papel central das alterações moleculares na detecção precoce do tumor. O desafio agora é aprender a usar as características moleculares individuais do tumor de cada paciente e melhorar as formas atuais de detecção e de tratamento, visando à prevenção do aparecimento e ao diagnóstico precoce do tumor. Atualmente, dois são os métodos já amplamente utilizados nos Estados Unidos para caracterizar molecularmente os tumores mamários: MammaPrint e OncotypeDX. Este trabalho teve por objetivo discutir esses dois métodos prognósticos do câncer de mama, visando estabelecer diferenças entre eles e suas principais aplicações.

##plugins.themes.bootstrap3.article.details##

Seção
Artigos de Revisão

Referências

1. Bacchi CE, Prisco F, Carvalho FM, Ojopi EB, Saad ED. Potencial impacto econômico do painel de expressão de 21 genes no tratamento adjuvante do câncer de mama no Brasil. Rev Assoc Med Bras. 2010;56(2):186-91. http://dx.doi.org/10.1590/S0104-42302010000200017

2. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008;14(24):8019-26. http://dx.doi.org/10.1158/1078-0432.CCR-08-0974

3. Linhares JJ, Silva ID, Souza NC, Noronha EC, Ferraro O, Baracat FF. Polimorfismo do gene do receptor de progesterona (progins) em mulheres com câncer de mama: estudo caso-controle. Rev Bras Ginecol Obstet. 2005;27(8):473-8. http://dx.doi.org/10.1590/S0100-72032005000800007

4. Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2005;14(3):656-61. http://dx.doi.org/10.1158/1055-9965.EPI-04-0001

5. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296(2):193-201. http://dx.doi.org/10.1001/jama.296.2.193

6. Azevedo G, Mendonça S. Câncer na população feminina brasileira. Rev Saude Publica. 1993;27(1):68-75.

7. Koifman RJ, Koifman S, Vieira RJS. Familial aggregation of breast/ ovarian cancer: age of onset along subsequent generations in Brazil. Cad Saude Publica. 1998;14(Suppl. 3):181-5. http://dx.doi.org/10.1590/S0102-311X1998000700019

8. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005;7(3):86-95. http://dx.doi.org/10.1186/bcr1021

9. Dufloth RM, Carvalho S, Heinrich JK, Shinzato YJ, Santos CC, Zeferino LC et al. Análise de mutações nos genes BRCA1 e BRCA2 em pacientes brasileiros com carcinoma de mama e história familiar positiva. São Paulo Med J. 2005;123(4):192-7. http://dx.doi.org/10.1590/S1516-31802005000400007

10. Berstein JL, López-Carrillo L, Wang L. The epidemiology of HER-2/neu and P53 in breast cancer. Salud Publica Mex. 1999;41(Suppl 2):S114-23. http://dx.doi.org/10.1590/S0036-36341999000800008

11. Corvalán A. Perfiles de expresión génica en decisiones terapéuticas en cáncer de mama. Rev Med Chile. 2007;135(2):257-63. http://dx.doi.org/10.4067/S0034-98872007000200016

12. Margarit S. Cáncer hereditario de mama. Rev Chil Radiol. 2008;14(3):135-41. http://dx.doi.org/10.4067/S0717-93082008000300006

13. Shahi PK, Manga GP. Subtipos clínicos y genéticos de câncer de mama: individualización del tratamiento. An Med Interna. 2007;24(12):569-70.

14. Roa JC, Anabalón L, Tapia O, Martínez J, Araya JC, Villaseca M, et al. Promoter methylation profile in breast cancer. Rev Med Chil. 2004;132(9):1069-77.

15. Fonseca FL, Soares HP, Manhani AR, Bendit I, Novaes M, Zatta SM, et al. Peripheral blood c-erbB-2 expression by reverse transcriptasepolymerase chain reaction in breast cancer patients receiving chemotherapy. 2002;3(3):201-5.

16. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breas cancer: pathways to personalized medicine. Clin Cancer Res. 2008;14(24):7988-99. http://dx.doi.org/10.1158/1078-0432.CCR-08-1211

17. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of amoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26. http://dx.doi.org/10.1056/NEJMoa041588

18. Paik S, Tang G, Shak S, Kim C, Baker K, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor: positive breast cancer. J Clin Oncol. 2006;24(23):3726-34. http://dx.doi.org/10.1200/JCO.2005.04.7985

19. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study. J Clin Oncol. 2010;28(11):1829-34. http://dx.doi.org/10.1200/JCO.2009.24.4798

20. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogenreceptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65. http://dx.doi.org/10.1016/S1470-2045(09)70314-6

21. Paik SS, Shak G, Tang C, Kim J, Baker M, Cronin D, et al. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. J Clin Oncol. 2005;23(Suppl 16S):510.

22. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, et al. Prognostic utility of the 21-gene assay in hormone receptor–positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26(25):4063-71. http://dx.doi.org/10.1200/JCO.2007.14.4501

23. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. Multi-gene RTPCR assay for predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14. Breast Cancer Res Treat. 2003; 82:A16.

24. Esteban J, Baker J, Cronin ML, Liu MG, Llamas MG, Walker R, et al. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue. ASCO Annual Meeting. 2003. Abstract 3416.

25. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Baker JCronin M, Liu ML, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11(24 Pt 1): 8623-31. http://dx.doi.org/10.1158/1078-0432.CCR-05-0735

26. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res. 2005;11(9):3315-19. http://dx.doi.org/10.1158/1078-0432.CCR-04-1707

27. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23(29):7265-77. http://dx.doi.org/10.1200/JCO.2005.02.0818

28. Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer. 2010;116(13):3112-8. http://dx.doi.org/10.1002/cncr.25206